COMPASS Pathways plc Annual Report - How They Did This Year

I’ve put together this guide to help you understand how COMPASS Pathways performed this year. Instead of digging through dense legal filings, we’ll break down the essentials so you can see where the company stands.

1. What does this company do?

COMPASS Pathways is a mental health biotech company focused on psychedelic-based therapy. Their lead candidate, COMP360, is a synthetic version of psilocybin designed to treat treatment-resistant depression, PTSD, and anorexia.

The company is currently in the research phase. They are investing heavily to prove their treatments work before they can bring them to market. As of late 2024, they have no commercial products and are not yet generating revenue.

2. Major wins: The clinical trial race

The company reached significant milestones in 2025 and early 2026 by completing major Phase 3 trials for treatment-resistant depression.

• COMP005 trial: A single 25mg dose of COMP360 significantly reduced depression scores compared to a placebo after six weeks.
• COMP006 trial: A second 25mg dose, administered three weeks after the first, provided sustained relief through week 12.

Based on these results, the company has requested a "rolling submission" from the FDA. This process allows them to submit sections of their application as they are completed, which may accelerate the final review timeline.

3. Financial health: Still in "burn" mode

The company is not yet profitable. They reported a loss of approximately $115 million for the year ending December 31, 2024. They ended the year with $210 million in cash reserves. Additionally, they have a loan agreement with Hercules Capital for up to $100 million; they have already drawn $50 million, with the remainder accessible upon hitting specific milestones.

The catch: The loan agreement requires the company to maintain a minimum cash balance of $40 million. If the company burns through cash faster than anticipated or misses clinical milestones, they may need to raise additional capital by issuing new shares. For investors, this could result in dilution, where your ownership percentage decreases and the stock price may be negatively impacted.

4. Key risks

• Concentration Risk: The company’s valuation is tied almost entirely to the success of COMP360. If the FDA does not approve the drug, the company’s value would likely decline significantly.
• Operational Logistics: The treatment requires a 6-to-8-hour supervised session with trained therapists. The company must successfully scale this model and secure reimbursement from insurance providers to achieve commercial viability.
• Regulatory Environment: COMP360 is a strictly controlled substance. The company must adhere to rigid DEA regulations. Any changes in federal policy or failure to maintain compliance could prevent the distribution of the therapy, even if it receives FDA approval.

5. The bottom line

COMPASS is a high-risk, high-reward opportunity. They have successfully cleared major clinical trial hurdles, which is a significant step toward commercialization. However, they remain a pre-revenue company with a monthly burn rate of approximately $9–$10 million. Your investment thesis should center on their ability to secure final FDA approval, establish a scalable delivery infrastructure, and gain insurance coverage for their patients.